17-Alpha-Substituted 11-Beta-Substituted-4-Aryl and 21-Substituted 19-Norpregnadienedione as Antiprogestational Agents
United Kingdom
10010646.7
Filed on 2001-03-16
10010646.7
Filed on 2001-03-16
17-Alpha-Substituted 11-Beta-Substituted-4-Aryl and 21-Substituted 19-Norpregnadienedione as Antiprogestational Agents
France
10010646.7
Filed on 2001-03-16
10010646.7
Filed on 2001-03-16
17-Alpha-Substituted 11-Beta-Substituted-4-Aryl and 21-Substituted 19-Norpregnadienedione as Antiprogestational Agents
Spain
10010646.7
Filed on 2001-03-16
10010646.7
Filed on 2001-03-16
17-Alpha-Substituted 11-Beta-Substituted-4-Aryl and 21-Substituted 19-Norpregnadienedione as Antiprogestational Agents
Germany
10010646.7
Filed on 2001-03-16
10010646.7
Filed on 2001-03-16
17-Alpha-Substituted 11-Beta-Substituted-4-Aryl and 21-Substituted 19-Norpregnadienedione as Antiprogestational Agents
Switzerland
10010646.7
Filed on 2001-03-16
10010646.7
Filed on 2001-03-16
17-Alpha-Substituted 11-Beta-Substituted-4-Aryl and 21-Substituted 19-Norpregnadienedione as Antiprogestational Agents
Belgium
10010646.7
Filed on 2001-03-16
10010646.7
Filed on 2001-03-16
17-Alpha-Substituted 11-Beta-Substituted-4-Aryl and 21-Substituted 19-Norpregnadienedione as Antiprogestational Agents
Austria
10010646.7
Filed on 2001-03-16
10010646.7
Filed on 2001-03-16
USE OF RECOMBINANT HUMAN UTEROGLOBIN IN TREATMENT OF INFLAMMATORY AND FIBROTIC CONDITIONS
Japan
1999-500979
Filed on 1999-11-29
1999-500979
Filed on 1999-11-29
TARGET ACTIVATED MICRODISSECTION
Patent Cooperation Treaty
PCT/US2015/034930
Filed on 2015-06-09
PCT/US2015/034930
Filed on 2015-06-09